| Objective To investigate the relationship between serum semaphorin3A (Sema3A) level and bone mineral density (BMD) and bone metabolic indicators in type 2 diabetic patients. Methods A total of 129 patients with type 2 diabetes were selected and divided into osteoporosis group (n = 62) and non-osteoporosis group (n = 67). The clinical data of these patients were collected and the biochemical indicators, bone metabolic indexes, and BMD were measured. The serum Sema3A level was detected using enzyme-linked immunosorbent assay (ELISA). The relationship between serum Sema3A and BMD and various bone metabolic indexes was analyzed with Spearman correlation analysis and multiple regression analysis. Results The level of serum Sema3A in type 2 diabetic patients with osteoporosis was lower than that of patients in non-osteoporosis group (P < 0.05). Spearman correlation analysis showed that the level of serum Sema3A was positively correlated with lumbar spine BMD, total hip BMD, and femoral neck BMD (r=0.310, r=0.239, r=0.203, all P<0.05), and negatively correlated with OC (r=?0.177, P<0.05), and negatively correlated with PINP, β-CTX, but with no statistical significance (P>0.05). Multiple regression analysis showed that there was a positive correlation between serum Sema3A and lumbar spine BMD (B=0.002, P=0.035) after correcting for confounding factors. Conclusion In patients with type 2 diabetes, the level of serum Sema3A decreases significantly in the osteoporosis group. Sema3A is positively correlated with BMD, but negatively correlated with OC, PINP, and β-CTX. |